Brief: BioArctic Says FDA Grants Priority Review To Leqembi Iqlik Supplemental Application
26/01/2026 02:48
Jan 25 (Reuters) - BioArctic AB BIOAb.ST: LEQEMBI® IQLIK™ (LECANEMAB-IRMB) SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION REGARDING SUBCUTANEOUS STARTING DOSE GRANTED PRIORITY REVIEW BY THE US FDA BIOARCTIC AB - PDUFA ACTION DATE FOR LEQEMBI IQLIK SET FOR MAY 24, 2026 Source text: ID:nPnt0jT9a Further company coverage: [BIOAb.ST] ((Reuters.briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln